UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
A big investment bank's expert looked at Pacific Biosciences and decided to rate it as "in-between"—not clearly good or bad—with a lower price guess of $1.35. This means experts see some challenges ahead, so it's worth watching what the company actually does rather than expecting big jumps.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.